Vlado Perkovic's Publications

• Effect of Iptacopan on Proteinuria and Complement Biomarkers in IgAN: Interim Analysis of the Phase 3 APPLAUSE-IgAN Study

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Effect of Semaglutide on Mortality Outcomes in the FLOW Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Prognostic Enrichment Using the Klinrisk Model: Insights from Landmark Kidney Disease Clinical Trials

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Risk-Based Implementation of SGLT2 Inhibitors: Insights from the CANVAS Program and CREDENCE Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Cardiovascular, Kidney, and Safety Outcomes with Canagliflozin in Older Adults: A Pooled Secondary Analysis of the CANVAS Program and CREDENCE Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Assessing the Quality of Care for People with CKD: A Systematic Review and Meta-Analysis

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.

  Journal articles

  2024

  NEJM Evid

• The Effects of Anti-Inflammatory Agents on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials

  Journal articles

  2024

  Heart, Lung and Circulation

• WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY

  Journal articles

  2024

  Kidney International Reports

• WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY

  Journal articles

  2024

  Kidney International Reports

• WCN24-1001 EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY

  Journal articles

  2024

  Kidney International Reports

• WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL

  Journal articles

  2024

  Kidney International Reports

• Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.

  Journal articles

  2023

  New England Journal of Medicine

• Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression

  Journal articles

  2023

  Journal of the American Society of Nephrology

• Effect of SGLT2 Inhibitors on Discontinuation of Reninangiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

  Journal articles

  2023

  Journal of the American Society of Nephrology

• The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial

  Journal articles

  2023

  Diabetes, Obesity and Metabolism

• Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide

  Journal articles

  2023

  European Heart Journal

• Estimated Lifetime Benefits of Combination Therapy With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-Steroidal MRAs in Patients With Type 2 Diabetes and Albuminuria

  Journal articles

  2023

  CIRCULATION

• Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials

  Journal articles

  2023

  Diabetes, Obesity and Metabolism

• The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

  Journal articles

  2023

  Nephrology Dialysis Transplantation

• Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial

  Journal articles

  2023

  Circulation

• The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials

  Journal articles

  2023

  Diabetes, Obesity and Metabolism

• Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials

  Journal articles

  2023

  Diabetes, Obesity and Metabolism

• Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials

  Journal articles

  2023

  Nephrology Dialysis Transplantation

• Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

  Journal articles

  2023

  Journal of the American Heart Association